China's Biomedical Industry Competitiveness Upgrade Path
Biomedical industry in China more competitive in the path
?? Biomedical industry as an example of Shanghai
I. Development of China's biomedical industry and means of
Biotechnology in China based on 70 years follow-up study carried out into the 90's, started in the field of medicine and agriculture industrialization process. Compared with developed countries, China's market is small, but the growth rate significantly higher than the global market growth. Domestic bio- Pharmaceutical market Not yet formed a monopoly competition, industry concentration is low, the majority of enterprises are small-scale development phase. In general, showed the following characteristics: First, there are considerable reserves of talent and technology. Currently engaged in biotechnology research and development staff for almost 2 million people, more and more students to study abroad have returned, bringing advanced technology. Take 1% of the work of the Human Genome Project and the Chinese genome project start-up, for the establishment of gene banks for the Chinese nation and laid a good foundation for the research of genetically modified plants and animals has yielded some results. Second, China has unique biological resources. Uneven economic development, making China both the developed and developing various diseases, with disease-related genes provides a unique resource; has good diversity; China's animal and plant resources are very rich. Third, many factors contribute to the development of the industry. Support of national policy, Pharmaceutical Industry Attention to the introduction of venture capital investors agree that the second board market will facilitate the establishment of more rapid development of the industry. State Drug Administration of various New Drugs Appropriate extension of protection. At present, some listed companies in the biomedical field, while the risk of investment for the industry has begun operation. Fourth, patent risk will be gradually released. Some enterprises in China and some foreign generic biological products will be joined WTO, the impact of intellectual property protection, but many products patent is about to expire, so that these companies produce these products, the risk of gradual release.
Join the WTO, China's biomedical industry faces the impact of the biological drugs, the import tariff from the point of view, the current Preparation Drug import tariff is 20%; "WTO" after 10 years will be reduced to 6.5% level. The impact of foreign direct access. Many biological systems in the world Pharmaceutical companies Industry have been directly or indirectly enter the Chinese market, they not only approved drugs themselves quickly registered in China, while production line built in China production, and some clinical trials of new drug development will be moved to China to complete. The impact of foreign drug development. 1997 U.S. biotechnology venture capital has more than 50 billion U.S. dollars, and the additional annual investment of 50 billion U.S. dollars, while China's 10 years on the total input biopharmaceutical less than 40 billion yuan. Intellectual property disputes. IP protection greatly limit the domestic manufacturers of imitation behavior, and our very few drugs with independent property rights.
Overall, China's biomedical industry shows a small scale, started late feature, with Europe and the United States, Japan and other advanced countries is also at a disadvantage. From the perspective of industry life cycle, biological pharmaceutical industry in the industrial growth phase, and will have strong market prospects, is contested national industry competition. From a global point of view, after years of development and market competition, coupled with the government lost no time to boot, many developed countries in technology, personnel, capital-intensive areas, has gradually formed a bio-gathering area, thus forming a more perfect bio-pharmaceutical industry chain and industry cluster. The United States has formed a San Francisco, Boston, Washington, North Carolina, five San Diego area biotechnology industry. Silicon Valley biotech industry which accounts for the U.S. biotechnology industry employed more than half of employees, sales revenue in the U.S. biotechnology industry, 57%, R & D investment accounted for 59% of their annual sales growth rate of nearly 40%. Besides the U.S., the UK's Cambridge genome Park, the southern suburbs of Paris, France, the gene Valley, Germany bio-technology demonstration areas, biological park in Bangalore, India, gathered, including biotech companies, research, technology transfer centers, banking, investment, services, etc., large number of institutions, providing a large number of employment opportunities and most of the output. The biotechnology industry clusters in these countries and regions in the budding industrial structure, expanding the scale of the industry, enhance industrial competitiveness and made important contributions.
Therefore, the development of China's biomedical industry is the most critical training and development of strong regional biomedical cluster.
China's Biomedical Industry Competitiveness Upgrade Path
By: frbiz2@foxmail.com
Aarkstore Enterprise---consort Medical Plc (csrt) - Financial And Strategic Analysis Review Medical Accidents - Clinical Negligence Claims Orange County Medical Marijuana Patients - Learn To Grow Your Own Medicine! Why Taking Weight Loss Drugs? Emergency Medical Support Made Available Within Minutes Medical Billing And Coding Occupations In The Medical Industry For Any Skilled Worker Canpharm Canada Pharmacy - Lowest Price On Prescription Drugs Guaranteed! Weight Loss Without Medicines Anti-depressant Medicines Work On Nerve Cells In The Brain. Three Reasons Natural Healing College Is Better Than California College Of Natural Medicine Best Mold Doctors: Mold Remediation Contractors Florida Medical Facility Hvac Services In Florida Knee Joint Pain Treatments: Proven Medical Methods To Reduce Knee Pain